Clinical Trials Directory

Trials / Unknown

UnknownNCT03742492

Bioavailability of EPA + DHA Enriched Canned Tuna and Its Acute Effects

Bioavailability of EPA + DHA Enriched Canned Tuna and Its Acute Effects on Cardiovascular Risk Markers, in Healthy Human Volunteers

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
28 (estimated)
Sponsor
Universidade do Porto · Academic / Other
Sex
All
Age
18 Years – 59 Years
Healthy volunteers
Accepted

Summary

Evidence has suggested that omega-3 fatty acids, namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have an important role in promoting cardiovascular health. However, the currently available scientific literature describing the postprandial effects and bioavailability of these fatty acids, particularly when they are incorporated into high protein food item, like canned tuna, is far from conclusive. The aim of this study is to evaluate the acute bioavailability of EPA + DHA enriched canned tuna and its acute effects on cardiovascular risk markers, in healthy human volunteers.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTMeal containing canned tuna + fish oil (5 g EPA + DHA)Meal containing canned tuna + fish oil (5 g EPA + DHA)
DIETARY_SUPPLEMENTMeal containing canned tuna + soybean oilMeal containing canned tuna + soybean oil

Timeline

Start date
2018-09-19
Primary completion
2019-06-01
Completion
2019-07-01
First posted
2018-11-15
Last updated
2019-05-30

Locations

1 site across 1 country: Portugal

Source: ClinicalTrials.gov record NCT03742492. Inclusion in this directory is not an endorsement.